PLRX

Over the past six months, Pliant Therapeutics' stock has underperformed the S&P500 Index by -32.31%. Key events include the presentation of interim Phase 1 results for PLN-101095 in December 2025. In March 2026, the company provided a corporate update and reported Fourth Quarter 2025 financial results, with stock changes of +6.02% and -3.76%. In April 2026, updated data from the Phase 1 trial of PLN-101095 were presented, the first patient was dosed in the FORTIFY trial, and the CFO's stock options were repriced. In May 2026, Pliant Therapeutics is expected to participate in the RBC Capital Markets Global Healthcare Conference and announce its Q1 2026 earnings.